2023 World Conference on Lung Cancer (Posters)-P2.09. Treatment Adherence Disparities and Clinical Outcomes of Osimertinib among Ethnic-Minority Patients with EGFR-Mutated NSCLC

P2.09. Treatment Adherence Disparities and Clinical Outcomes of Osimertinib among Ethnic-Minority Patients with EGFR-Mutated NSCLC - PDF(Abstract)

Back to course

Pdf Summary

A study presented at the WCLC 2023 conference examined the treatment adherence and clinical outcomes of Osimertinib, a targeted therapy for EGFR-mutated non-small cell lung cancer (NSCLC), in ethnic-minority patients. The study included 100 patients with EGFR-mutated NSCLC who received Osimertinib between January 2016 and December 2022. The researchers evaluated overall survival (OS), progression-free survival (PFS), and treatment adherence measured by medication possession ratio (MPR) and proportion of days covered (PDC).<br /><br />The results showed that there were no significant differences in treatment adherence between different racial/ethnic groups. Hispanics had lower income compared to non-Hispanics, but this did not affect treatment adherence or out-of-pocket costs for Osimertinib. Univariate analysis showed a higher risk of mortality in Hispanics compared to non-Hispanic whites. Multivariate analysis revealed a higher risk of death in Black patients compared to non-Black patients. Non-adherence to Osimertinib, as measured by PDC, was also associated with a higher risk of death.<br /><br />The study highlights potential survival disparities among minority patients and those with lower incomes who are treated with Osimertinib. It emphasizes the importance of optimizing Osimertinib usage and clinical outcomes in real-world settings. Further research is needed to address socioeconomic healthcare disparities and improve treatment adherence in order to reduce the risk of death in patients with EGFR-mutated NSCLC.

Asset Subtitle

Matthew Lee

Meta Tag

Speaker Matthew Lee

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

WCLC 2023 conference

Osimertinib

EGFR-mutated non-small cell lung cancer

ethnic-minority patients

treatment adherence

overall survival

progression-free survival

medication possession ratio

racial/ethnic groups

mortality risk